Directors Dealings

Lawrence A. Rosen,

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

4,338

Metin Colpan,

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

4,243

Toralf Haag,

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

1,815

Ross L. Levine,

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

3,803

Elaine R. Mardis,

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

3,998

Elizabeth E. Tallett

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

4,487

Thierry Bernard,

Managing Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

106,903

Roland Sackers,

Managing Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

79,753

All Supervisory Board Directors ²⁾

02/28/25 Grant

Restricted Stock Units

5,990

Thierry Bernard,

Managing Director

02/28/25 Grant

Performance Stock Units

143,229

Roland Sackers,

Managing Director

02/28/25 Grant

Performance Stock Units

80,098

Thierry Bernard,

Managing Director

02/27/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

434

Roland Sackers,

Managing Director

02/27/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

4,736

Lawrence A. Rosen,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

415

Metin Colpan,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

4,910

Toralf Haag,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

73

Ross L. Levine,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

465

Elaine Mardis,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

114

Elizabeth E.Tallett,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

1,351

Stephen H. Rusckowski,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

1

Thierry Bernard,

Managing Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

8,919

Roland Sackers,

Managing Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

10,951